HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

apratoxin A

a potent cytotoxin with a novel skeleton, has been isolated from the marine cyanobacterium Lyngbya majuscula Harvey ex Gomont; structure in first source

Networked: 11 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - Depsipeptides: 297
      - apratoxin A: 11
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - Depsipeptides: 297
      - apratoxin A: 11

Experts

1.	Doi, Takayuki: 3 articles (10/2017 - 07/2010)
2.	Luesch, Hendrik: 3 articles (11/2011 - 06/2008)
3.	Masuda, Yuichi: 2 articles (10/2017 - 09/2014)
4.	Onda, Yuichi: 2 articles (10/2017 - 09/2014)
5.	Yoshida, Masahito: 2 articles (10/2017 - 09/2014)
6.	Gerwick, William H: 2 articles (01/2016 - 07/2010)
7.	Liu, Yanxia: 2 articles (11/2011 - 07/2009)
8.	Ishmael, Jane E: 1 article (01/2020)
9.	Kawaguchi, Shinsaku: 1 article (01/2020)
10.	Kazemi, Soheila: 1 article (01/2020)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 11/10/2011 - "Our structure-activity relationship studies and medicinal chemistry efforts led to a potent inhibitor with in vivo efficacy in a colorectal tumor xenograft model without irreversible toxicity exerted by apratoxin A, demonstrating that this novel mechanism of action has therapeutic potential."
2.	Neoplasms (Cancer) 10/01/2017 - "Moreover, compared to apratoxin A, apratoxin M16 exhibited a similarly high level of growth inhibitory activity against various cancer cell lines. " 01/01/2016 - "Apratoxin A is a natural product with potent antiproliferative activity against many human cancer cell lines. " 06/13/2001 - "Apratoxin A (1) possesses IC(50) values for in vitro cytotoxicity against human tumor cell lines ranging from 0.36 to 0.52 nM; however, it was only marginally active in vivo against a colon tumor and ineffective against a mammary tumor." 01/01/2020 - "Remarkably, CbA, apratoxin A, and ipomoeassin F do not display comparable patterns of potency and selectivity in the NCI60 panel of human cancer cell lines. " 07/05/2010 - "Additional assays using zone inhibition of cancer cells and clonogenic cells give a comparison of the activities of apratoxin F to apratoxin A. "
3.	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 11/01/2022 - "In addition to the above, Moorea sp. produce apratoxin A and dolastatin 15 possessing anti cancerous activity but unfortunately till date only brentuximab vedotin (trade name Adcetris), a medication derived from marine peptides, for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma has been approved by FDA. "
4.	Hodgkin Disease (Hodgkin's Disease) 11/01/2022 - "In addition to the above, Moorea sp. produce apratoxin A and dolastatin 15 possessing anti cancerous activity but unfortunately till date only brentuximab vedotin (trade name Adcetris), a medication derived from marine peptides, for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma has been approved by FDA. "
5.	Dehydration (Water Stress) 06/01/2008 - "The 5- to 15-fold reduced activity compared with apratoxin A (2) is attributed to the dehydration in the long-chain polyketide unit, which could affect the conformation of the molecule."

Related Drugs and Biologics

1.	Polyketides
2.	Depsipeptides
3.	Phosphotransferases (Kinase)
4.	Peptides (Polypeptides)
5.	Cytotoxins (Cytolysins)
6.	Brentuximab Vedotin
7.	apratoxin F
8.	ipomoeassin F
9.	erastin
10.	apratoxin C